

Applicant: Fitzhugh et al. Serial No.: 10/623239 Filed: July 17, 2003

Title: Highly Cross-Linked,

Extremely Hydrophobic Nitric Oxide-Releasting Polymers & Methods for Their Manufacture & Use

Group Art Unit: Unassigned Examiner: Unassigned

Docket No.: 14364.99

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents Mail Stop DD P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. § 1.56, Applicants submit herewith patents, publications, or other information of which they are aware that may be considered in connection with the above-referenced patent application. Submission of this Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein is "material" to Applicants' invention as that term is currently defined in 37 C.F.R. § 1.56 (37 CFR § 1.97(h).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other relevant information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

A Patent and Trademark Office Form 1449 listing each of these informational items is enclosed along with a copy of each item. A copy of the cited references are not included. Copies can be found in the parent case, U.S. application serial number 09/972219 filed October 4, 2001.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action issued on the merits of the subject application in accordance with 37 C.F.R. §1.97(b)(3). In the event that a first Office Action has been mailed to the undersigned prior to the mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge payment of the applicable fee pursuant to 37 C.F.R. § 1.17(p) to Deposit Account No. 50-1329. A duplicate copy of this document is enclosed.

Respectfully submitted,

September 2, 2003

Louis C. Cullman Registration No. 39,645

STRADLING YOCCA CARLSON & RAUTH

660 Newport Center Drive, Suite 1600

Newport Beach, CA 92660 Telephone: 949.725.4000 Facsimile: 949.725.4100

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, to persons are required to respond to a collection of information unless it contains a valid OMB control

		701.61	num	ber.	
Substitute for for	rm 1449A/PTO	با	\	Comple	ete if Known
	(	SEP 0 4 2003 %		A E Ai No b	1 00/070 010
) ·	14	k G	<i>!</i>	Application Number	09/972,219
l IN	IFORMATION	<b>DISCLOSUR</b>	E	Filing Date	10/04/2001
S	STATEMENT BY APPLICANT			First Named Inventor	Fitzhugh et al.
				Group Art Unit	1616
	(use as many she	ets as necessary)		Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	17363-20

		II.C. Detect		U.S. PATENT DOCUME		I Dane Ochumna Lines 18th
Examiner Initials	Cite No.1	U.S. Patent I  Number	Kind Code <sup>2</sup>	Date of Publications of Cited  Documents  MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		4954526		09/04/1990	Keefer	
		5039705		08/13/1991	Keefer et al.	
		5155137		10/13/1992	Keefer et al.	
		5171217		12/15/1992	March et al.	
		5212204		05/18/1993	Keefer et al.	
		5229172		07/20/1993	Cahalan et al.	
•		5250550		10/05/1993	Keefer et al.	
		5268465		12/07/1993	Bredt et al.	
		5366997		11/22/1994	Keefer et al.	
		5380758		01/10/1995	Stamler et al.	
		5405919		04/11/1995	Keefer et al.	
		5428070		06/27/1995	Cooke et al.	
		5468630		11/21/1995	Billiar et al.	
·		5482925		01/09/1996	Hutsell	
		5519020		05/21/1996	Smith et al.	
		5525357		06/11/1996	Keefer et al.	
		5574068		11/12/1996	Stamler et al.	
		5583101		12/10/1996	Stamler et al.	
····		5632981		05/27/1997	Saavedra et al.	
		5650447		07/22/1997	Keefer et al.	
		5658565		08/19/1997	Billiar et al.	
		5676963		10/14/1997	Keefer et al.	
		5683668		11/04/1997	Hrabie et al.	
		5691423		11/25/1997	Smith et al.	
		5700830		12/23/1997	Korthuis et al.	
		5714511		02/03/1998	Saavedra et al.	
	,	5718892		02/17/1998	Keefer et al.	
		5721365		02/24/1998	Keefer et al.	
		5770645		06/23/1998	Stamler et al.	
		5789447		08/04/1998	Wink, Jr. et al.	
		5814656	<del>                                     </del>	09/29/1998	Saavedra et al.	
		5814667		09/29/1998	Mitchell et al.	
Examine	<u></u>		<u> </u>		Date	
Signature	-				Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) in this box →⊠

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, as persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form	1449A/PTO	SEP 0 4 2	~ <u>[3]</u>	Comple	ete if Known
j		\ <del>\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\</del>	4.1	Application Number	09/972,219
INF	ORMATION	DISCLOSUF	3 <b>6</b> 7	Filing Date	10/04/2001
ST	ATEMENT E	BY APPERCAN	A CONTRACTOR	First Named Inventor	Fitzhugh et al.
				Group Art Unit	1616
(L	use as many she	ets as necessary)		Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	17363-20

	5837313	11/17/1998	Ding et al.	
	5837736	11/17/1998	Mitchell et al.	
	5840759	11/24/1998	Mitchell et al.	
	5877216	03/02/1999	Place et al.	
-	5891459	04/06/1999	Cooke et al.	
	5910316	06/08/1999	Keefer et al.	, , , , , , , , , , , , , , , , , , ,
	5945452	08/31/1999	Cooke et al.	***
-	5958427	09/28/1999	Salzman et al.	
	5962520	10/05/1999	Smith et al.	
	5994444	11/30/1999	Trescony et al.	
	6024918	02/15/2000	Hendriks et al.	

				FC	DREIGN PATENT DOCUMENTS	3		
- Functions	Cita	Fore Office <sup>3</sup>	eign Patent Docur	ment Kind	Name of Detentor or Applicant of	Date of Publications of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant	T⁵
Examiner Initials	Cite No. <sup>1</sup>	WO	00/02501	Code	Name of Patentee or Applicant of Cited Document  William Harvey Research LTD.	MM/DD/YYYY 01/20/00	Figures Appear	

		OTHER PRIOR ART / NON PATENT LITERATURE DOCUMENTS	
Examiner Initials'	Cite No.1	publisher, city and/or country where published.	T²
		Bauer et al.; Evaluation of Linear Polyethyleneimine/nitric Oxide Adduct on Wound Repair: Therapy versus Toxicity; Wound Repair & Regeneration, November/December 1998, pp. 569/577	
		Chandy et al; "Use of Plasma Glow for Surface/Engineering Biomolecules to Enhance Bloodcompatibility of Dacron and PTFE Vascular Prosthesis." Biomaterials 21: 699/712	
		Drago; "Free Radicals in Inorganic Chemistry." No. 36, Advances in Chemistry Series, American chemical society, Washington, D. C. 1962, pp. 143/149	
		Hanson et al; Nitric Oxide Donors: A Continuing Opportunity in Drug Design; Advances in Pharmacology, Vol 34, pp. 383/398	
		Hrabie et al; "New Nitric Oxide/Releasing Zwitterions Derived from Polyamines." J. Org. Chem. 1993, 58, 1472/1476	
		Jordi; Jordi Gel Columns for Size Exclusion Chromatography; Column Handbook for Size Exclusion Chromatography; 1999, pp. 367/425	
Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) in this box →⊠

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for for	m 1449A/PTO		num	Comple	ete if Known
j			4 2003 🗳	Application Number	09/972,219
IN	FORMATION TATEMENT E	I DISŒQSUF	RE	Filing Date	10/04/2001
S <sup>-</sup>	TATEMENT E	BY APPELOAD	ATARK CO	First Named Inventor	Fitzhugh et al.
				Group Art Unit	1616
	(use as many she	ets as necessary)		Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	17363-20

	Kaul et al.; Polymeric/Based Perivascular Delivery of a Nitric Oxide Donor Inhibits Intimal Thicening After Balloon Denudation Arterial Injury: Role of Nuclear Factor/kappaB; Journal of the American College of Cardiology, Vol. 35, No. 2, 2000:493/501
	Keefer et al; "NONOates" (1/Substituted Diazen/1/ium/1,2/diolates) as Nitric Oxide Donors: Convenient Nitric Oxide Dosage Forms." Methods in Enzymology, Vol 268: 281/293
	Mowery et al.; Preparation and Characterization of Hydrophobic Polymeric Films That Are Thromboresistant Via Nitric Oxide Release; Biomaterials 21 (2000) 9/21
-	Saavedra et al.; "Conversion of Polysaccharide to Nitric Oxide/Releasing Form Dual/Mechanism Anticoagulant Activity of Diasenium diolated Heparin." Bioorganic & Medicinal Chemistry Letters 10 (2000) 1/3
•	Smith et al.; Nitric Oxide/Releasing Polymers Containing the [N(O)NO]' Group; J. Med. Chem. 1996, 39, 1148/1156

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents, <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent documents, <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.